EA201790101A1 - Аналоги придопидина, их получение и применение - Google Patents

Аналоги придопидина, их получение и применение

Info

Publication number
EA201790101A1
EA201790101A1 EA201790101A EA201790101A EA201790101A1 EA 201790101 A1 EA201790101 A1 EA 201790101A1 EA 201790101 A EA201790101 A EA 201790101A EA 201790101 A EA201790101 A EA 201790101A EA 201790101 A1 EA201790101 A1 EA 201790101A1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
methylsulfonyl
dopopidine
provides
present
Prior art date
Application number
EA201790101A
Other languages
English (en)
Inventor
Малле Шмидт
Малле Пэри
Марит Лаос
Антс Масалу
Калле Кальйусте
Original Assignee
Тева Фармасьютикал Индастриз Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тева Фармасьютикал Индастриз Лтд. filed Critical Тева Фармасьютикал Индастриз Лтд.
Publication of EA201790101A1 publication Critical patent/EA201790101A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/24—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by sulfur atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8872—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample impurities

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Spectroscopy & Molecular Physics (AREA)

Abstract

В данном изобретении представлено выделенное соединение, имеющее структуру:или его соль. В данном изобретении также представлен способ получения 4-(3-(метилсульфонил)фенил)-1-пропилпиперидин-4-ола, 1-(3,3-бис-(3-(метилсульфонил)фенил)пропил)-4-(3-(метилсульфонил)фенил)пиперидона, 1,4-бис-((3-(1-пропилпиперидин-4-ил)фенил)сульфонил)бутана, (3R,4S)-4-(3-(метилсульфонил)фенил)-1-пропилпиперидин-3-ола, 1-оксида 4-(3-(метилсульфонил)фенил)-1-пропилпиперидина, 1-(2-метилпентил)-4-(3-(метилсульфонил)фенил)пиперидина, 4-(3-(метилсульфинил)фенил)-1-пропил-1,2,3,6-тетрагидропиридина и 4-(3-(метилсульфонил)фенил)-1-пропил-1,2,3,6-тетрагидропиридина. В данном изобретении также представлена примесь или ее соль для применения, в качестве ссылочного стандарта, для определения следов примеси в фармацевтической композиции, содержащей придопидин или его фармацевтически приемлемую соль. В данном изобретении также представлен способ получения лекарственного продукта придопидина, включающий получение лекарственного вещества придопидина и смешивания лекарственного вещества придопидина с подходящими наполнителями с получением лекарственного продукта придопидина. В данном изобретении также представлен способ получения лекарственного продукта придопидина. В данном изобретении также представлен способ продажи лекарственного продукта придопидина.
EA201790101A 2014-06-30 2015-06-29 Аналоги придопидина, их получение и применение EA201790101A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462019337P 2014-06-30 2014-06-30
US201462076436P 2014-11-06 2014-11-06
PCT/US2015/038349 WO2016003919A1 (en) 2014-06-30 2015-06-29 Analogs of pridopidine, their preparation and use

Publications (1)

Publication Number Publication Date
EA201790101A1 true EA201790101A1 (ru) 2017-06-30

Family

ID=54929343

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790101A EA201790101A1 (ru) 2014-06-30 2015-06-29 Аналоги придопидина, их получение и применение

Country Status (18)

Country Link
US (3) US10130621B2 (ru)
EP (2) EP4049998A1 (ru)
JP (2) JP6800842B2 (ru)
CN (2) CN106456618A (ru)
AU (1) AU2015284385B2 (ru)
BR (1) BR112016030968B1 (ru)
CA (1) CA2951494C (ru)
DK (1) DK3160470T3 (ru)
EA (1) EA201790101A1 (ru)
ES (1) ES2927888T3 (ru)
HK (1) HK1231406A1 (ru)
HU (1) HUE060242T2 (ru)
IL (2) IL249601B (ru)
MX (1) MX2016017332A (ru)
PL (1) PL3160470T3 (ru)
TW (1) TW201613859A (ru)
UY (1) UY36192A (ru)
WO (1) WO2016003919A1 (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
US11090297B2 (en) * 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
WO2023062632A1 (en) * 2021-10-11 2023-04-20 Prilenia Neurotherapeutics Ltd. Pridopidine and analogs thereof for the treatment of neurodegenerative eye disease
US11471449B2 (en) 2015-02-25 2022-10-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine to improve cognitive function and for treating Alzheimer's disease
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina
WO2017147366A1 (en) 2016-02-24 2017-08-31 Teva Pharmaceuticals International Gmbh Treatment of neurodegenerative eye disease using pridopidine
CA3151507C (en) 2016-08-24 2024-05-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating functional decline
AU2017315781B2 (en) 2016-08-24 2021-01-28 Prilenia Neurotherapeutics Ltd Use of pridopidine for treating dystonias
IL268125B2 (en) 2017-01-20 2023-04-01 Prilenia Neurotherapeutics Ltd Pridopidine for the treatment of fragile x syndrome
WO2019036358A1 (en) 2017-08-14 2019-02-21 Teva Pharmaceuticals International Gmbh METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS WITH PRIDOPIDINE
EP3675830A1 (en) 2017-08-30 2020-07-08 Prilenia Neurotherapeutics Ltd. High concentration dosage forms of pridopidine
MX2020002645A (es) 2017-09-08 2021-06-10 Prilenia Neurotherapeutics Ltd Pridopidina para el tratamiento de las discinesias inducidas por fármacos.
CA3128250C (en) * 2019-03-15 2024-01-16 Michael Hayden Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
WO2020250234A1 (en) * 2019-06-12 2020-12-17 Prilenia Neurotherapeutics Ltd. Composition comprising pridopidine and analog thereof for treating huntington disease and symptoms thereof
JP2023534095A (ja) * 2020-05-04 2023-08-08 プリレニア ニューロセラピューティクス リミテッド 選択的ｓ１ｒアゴニストを使用するウイルス感染、疾患、又は障害の治療
JP2023545846A (ja) * 2020-10-20 2023-10-31 プリレニア ニューロセラピューティクス リミテッド 不安及び抑うつを治療するためのプリドピジンまたはその類似体の使用
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途
IL307462A (en) * 2021-04-14 2023-12-01 Prilenia Neurotherapeutics Ltd Treatment of Huntington's disease in a prodromal state
CN114716391B (zh) * 2022-04-24 2023-12-12 杭州仟源保灵药业有限公司 一种醋甲唑胺杂质及其制备方法和应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6472736A (en) 1987-09-14 1989-03-17 Toshiba Corp Mri apparatus
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
CA2552560A1 (en) * 2004-01-21 2005-08-11 Teva Pharmaceutical Industries Ltd. Process for the preparation of valacyclovir hydrochloride
MXPA06013945A (es) * 2004-06-08 2007-10-08 Neurosearch Sweden Ab Piperidinas sustituidas, novedosas, como moduladores de la neurotransmision de dopamina.
SE0401465D0 (sv) 2004-06-08 2004-06-08 Carlsson A Research Ab New substituted piperdines as modulators of dopamine neurotransmission
US7629461B2 (en) * 2004-09-04 2009-12-08 Teva Pharmaceutical Industries Ltd Isolated valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard
CN101068782A (zh) * 2004-10-13 2007-11-07 神经研究瑞典公司 合成4－(3－磺酰基苯基)－哌啶类的方法
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
CN101094850A (zh) * 2005-01-03 2007-12-26 特瓦制药工业有限公司 具有较低水平杂质的奥美沙坦酯
SE529246C2 (sv) * 2005-10-13 2007-06-12 Neurosearch Sweden Ab Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
EP1961742A1 (en) 2007-02-22 2008-08-27 Novartis AG compounds of formula (I) as serine protease inhibitors
PT2146961E (pt) * 2007-04-12 2014-04-30 Ivax Int Gmbh Derivados de n-óxido e/ou di-n-óxido de estabilizadores / moduladores dos recetores da dopamina exibindo perfis de efeitos secundários cardiovasculares melhorados
ES2528040T3 (es) * 2007-06-18 2015-02-03 A.Carlsson Research Ab Uso de estabilizadores de dopamina
US20110206782A1 (en) * 2010-02-24 2011-08-25 Auspex Pharmaceuticals, Inc. Piperidine modulators of dopamine receptor
EP2598662A1 (en) 2010-07-02 2013-06-05 Aktiebolaget SKF Mechanical component and method for surface hardening
MX2013002453A (es) 2010-09-03 2013-08-01 Ivax Int Gmbh Analogos deuterados de pridopidina utiles como estabilizadores dopaminergicos.
CN103958469B (zh) 2011-09-07 2016-04-20 梯瓦制药国际有限责任公司 一种新的普利多匹定盐酸盐多晶型形态
EP2787997A4 (en) 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
MX2014011971A (es) 2012-04-04 2015-01-16 Ivax Int Gmbh Composiciones farmaceuticas para terapia de combinacion.
WO2014052933A1 (en) 2012-09-27 2014-04-03 Teva Pharmaceutical Industries Ltd. Laquinimod and pridopidine for treating neurodegenerative disorders
EP2900226A4 (en) 2012-09-27 2016-03-30 Teva Pharma COMBINATION OF RASAGILIN AND PRIDOPIDIN FOR TREATING NEURODEGENERATIVE DISORDERS, ESPECIALLY HUNTINGTON'S DISEASE
PE20160195A1 (es) 2013-06-21 2016-05-14 Teva Pharmaceuticals Int Gmbh Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
MX2016009427A (es) 2014-01-22 2016-12-08 Teva Pharmaceuticals Int Gmbh Formulaciones de pridopidina de liberacion modificada.
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
WO2016106142A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
EP3590512A1 (en) 2015-02-25 2020-01-08 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat epilepsy
EP3324967A4 (en) 2015-07-22 2019-03-20 Prilenia Therapeutics Development Ltd. PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME
AR105434A1 (es) 2015-07-22 2017-10-04 Teva Pharmaceuticals Int Gmbh Proceso para preparar pridopidina

Also Published As

Publication number Publication date
JP7035108B2 (ja) 2022-03-14
JP6800842B2 (ja) 2020-12-16
US10406145B2 (en) 2019-09-10
EP3160470B1 (en) 2022-08-03
IL272306A (en) 2020-03-31
WO2016003919A8 (en) 2017-01-26
HK1231406A1 (zh) 2017-12-22
CA2951494C (en) 2023-10-03
TW201613859A (en) 2016-04-16
PL3160470T3 (pl) 2022-11-21
IL249601B (en) 2020-01-30
BR112016030968A2 (pt) 2018-07-17
DK3160470T3 (da) 2022-10-24
CA2951494A1 (en) 2016-01-07
IL272306B (en) 2021-04-29
EP3160470A4 (en) 2018-01-10
CN106456618A (zh) 2017-02-22
IL249601A0 (en) 2017-02-28
EP3160470A1 (en) 2017-05-03
US20150374677A1 (en) 2015-12-31
JP2020143072A (ja) 2020-09-10
UY36192A (es) 2016-01-29
WO2016003919A1 (en) 2016-01-07
BR112016030968B1 (pt) 2023-11-21
US11141412B2 (en) 2021-10-12
US10130621B2 (en) 2018-11-20
US20200030308A1 (en) 2020-01-30
EP4049998A1 (en) 2022-08-31
HUE060242T2 (hu) 2023-02-28
US20190030016A1 (en) 2019-01-31
AU2015284385A1 (en) 2017-02-02
ES2927888T3 (es) 2022-11-11
MX2016017332A (es) 2017-05-12
AU2015284385B2 (en) 2021-01-21
JP2017519839A (ja) 2017-07-20
CN113511997A (zh) 2021-10-19

Similar Documents

Publication Publication Date Title
EA201790101A1 (ru) Аналоги придопидина, их получение и применение
CY1125613T1 (el) 4-ιμιδαζοπυριδαζιν-1-υλ-βενζαμιδια και 4- ιμιδαζοτριαζιν-1-υλ-βενζαμιδια ως αναστολεις βτκ
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
PH12018500259A1 (en) Muscarinic agonists
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
BR112015000229A2 (pt) formulações aquosas estáveis de etanercept
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
EA201691674A1 (ru) 1,2-замещенные циклопентаны в качестве антагонистов рецептора орексина
EA201890532A1 (ru) Новые аннелированные бензамиды
EA202191114A1 (ru) Производные пиридинилсульфонамида, фармацевтические композиции и их применение
CY1122170T1 (el) Ορβεπιταντη για τη θεραπευτικη αγωγη χρονιου βηχα
UA117154C2 (uk) Антагоністи s1p3
WO2016209978A3 (en) Thiol-ene based peptide stapling and uses thereof
WO2018005801A3 (en) Novel non-systemic tgr5 agonists
TR201819805T4 (tr) Flavaglin türevleri̇.
EA201891682A1 (ru) Производное азациклического амида, способ его получения и фармацевтическое применение
NZ705813A (en) Treatment of mild and moderate alzheimer’s disease
EA202191515A1 (ru) Фармацевтическая композиция, содержащая апиксабан
EA201792237A1 (ru) Фармацевтические составы
EA201591150A1 (ru) Твердая единая форма с высоким содержанием фексофенадина и способ ее получения
MX2017012022A (es) Compuestos organicos.
EA201991286A1 (ru) Твердая фармацевтическая композиция для перорального применения, содержащая тенофовир и эмтрицитабин